USPTO issued Patent No. US12590298B2 on March 31, 2026, granting exclusive rights to The Regents of the University of California for an ex vivo primary tumor model prepared from fresh tumor tissues. The patent (14 claims) covers methods for screening anti-cancer agents by culturing tumor tissues to generate endothelial cell outgrowths and testing candidate agents for their ability to kill these cells, indicating anti-angiogenesis efficacy.

Pharmaceutical companies, biotech firms, and academic researchers developing cancer therapeutics may need to review this patent to assess potential freedom-to-operate implications for drug screening programs. No immediate compliance actions or deadlines apply—patent grants establish intellectual property rights rather than regulatory obligations. Entities conducting angiogenesis-related drug discovery should consider whether their methods fall within the scope of the granted claims.